---
title: "TELA Bio gets lender consent to pause revenue covenant test"
url: "https://aibio.space/news/tela-bio-gets-lender-consent-pause-revenue-covenant-test/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-09-28"
section: "Debt Financing"
tickers: "NASDAQ:TELA"
source: "https://www.sec.gov/Archives/edgar/data/1561921/000110465926111920/tm2626521d1_8k.htm"
summary: "The consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent."
---

By the aibio.space news desk.

Sources

- [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1561921/000110465926111920/tm2626521d1_8k.htm)

[TELA](https://aibio.space/companies/tela-bio/)

2026-09-28

# TELA Bio gets lender consent to pause revenue covenant test

Tickers [TELA](https://aibio.space/companies/tela-bio/)

The consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent.

## Key facts

- **Company**: TELA Bio, Inc. (NASDAQ: TELA)

- **News type**: Debt Financing

- **Primary source**: [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1561921/000110465926111920/tm2626521d1_8k.htm)

*Office towers against a dusk sky. CC0, via rawpixel. The picture shows the field, not the companies named.*

TELA Bio, Inc. entered into a Limited Consent to its Credit Agreement and Guaranty on September 28, 2026, according to a Form 8-K. The consent was signed with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent, and with the lenders that make up the Required Lenders under the credit agreement.

The original Credit Agreement and Guaranty is dated November 13, 2025. Under the consent, the minimum Revenue covenant in Section 10.02 will not be tested for the fiscal quarters ending on or about September 30, 2026 and December 31, 2026.

The filing does not describe a new loan, a fee or a change to the interest rate. The company says the full text of the consent will be filed as an exhibit to its quarterly report on Form 10-Q for the quarter ended September 30, 2026.

TELA Bio is based in Malvern, Pennsylvania. Chief Executive Officer Heather Getz signed the filing. The filing names no placement agent or advisor.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

TELA

TELA Bio, Inc.

NASDAQ · United States

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/tela-bio-gets-lender-consent-pause-revenue-covenant-test/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TELA Bio gets lender consent to pause revenue covenant test", 2026-09-28, https://aibio.space/news/tela-bio-gets-lender-consent-pause-revenue-covenant-test/